<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005078</url>
  </required_header>
  <id_info>
    <org_study_id>99139</org_study_id>
    <secondary_id>U01CA062505</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-PHI-22</secondary_id>
    <secondary_id>CHNMC-IRB-99139</secondary_id>
    <secondary_id>NCI-T99-0068</secondary_id>
    <secondary_id>CDR0000067685</secondary_id>
    <nct_id>NCT00005078</nct_id>
  </id_info>
  <brief_title>Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors</brief_title>
  <official_title>Phase I Dose Escalation Study of Tirapazamine (NSC 130181) in Combination With Carboplatin and Paclitaxel in Advanced Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining tirapazamine, carboplatin, and&#xD;
      paclitaxel in treating patients who have advanced malignant solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of tirapazamine in combination with carboplatin and&#xD;
           paclitaxel in patients with advanced solid tumors who have or have not received prior&#xD;
           chemotherapy.&#xD;
&#xD;
        -  Assess the toxicity and preliminary efficacy of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this regimen in these patients.&#xD;
&#xD;
        -  Investigate potential predictors of response by studying patient tissue specimens after&#xD;
           receiving this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of tirapazamine. Patients are stratified according&#xD;
      to prior chemotherapy status (previously untreated vs previously treated).&#xD;
&#xD;
      Patients receive tirapazamine IV over 2 hours, paclitaxel IV over 3 hours, and carboplatin IV&#xD;
      over 30 minutes. Treatment continues every 21 days for a maximum of 8 courses in the absence&#xD;
      of unacceptable toxicity or disease progression. Some patients may continue therapy in the&#xD;
      absence of unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of tirapazamine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity. An additional 12 patients in the previously&#xD;
      untreated stratum are treated at the MTD.&#xD;
&#xD;
      Patients are followed indefinitely.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36-68 patients (18-34 per stratum) will be accrued for this&#xD;
      study within 12-18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">44</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tirapazamine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced or metastatic malignant solid tumor&#xD;
             not curable by resection or other standard therapy&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
               -  Brain metastases allowed provided controlled with surgical excision and/or&#xD;
                  radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 2 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
          -  No history of allergic reactions to appropriate diuretics or antiemetics administered&#xD;
             in conjunction with protocol chemotherapy (e.g., 5-HT3 antagonists)&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study therapy&#xD;
&#xD;
          -  No medical, social, or psychological factors that would preclude study therapy&#xD;
&#xD;
          -  No clinically significant hearing loss&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin and nitrosoureas) and&#xD;
             recovered&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
          -  No prior combination paclitaxel and carboplatin&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since other prior investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Shibata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lara PN Jr, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 1;9(12):4356-62.</citation>
    <PMID>14555506</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>May 15, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2003</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Tirapazamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

